The DOI matches its Crossref record; 124 of the 129 references it cites were found in a registry or an index.
Fibrates for primary prevention of cardiovascular disease events
Open accessAbstract
BACKGROUND: Fibrates are effective for modifying atherogenic dyslipidaemia, and particularly for lowering serum triglycerides. However, evidence that fibrates reduce mortality and morbidity associated with cardiovascular disease (CVD), or overall mortality and morbidity, in the primary prevention of CVD is lacking. OBJECTIVES: This Cochrane Review and meta-analysis aimed to evaluate the clinical benefits and harms of fibrates versus placebo or usual care or fibrates plus other lipid-modifying drugs versus other lipid-modifying drugs alone for the primary prevention of cardiovascular disease (CVD) morbidity and mortality. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid), Embase (Ovid), CINAHL (EBSCO), and Web of Science (all from inception to 19 May 2016). We searched four clinical trial registers (last searched on 3 August 2016) with the help of an experienced professional librarian. We searched the databases to identify randomised controlled trials (RCTs) evaluating the clinical effects of fibrate therapy in the primary prevention of CVD events. We did not impose any language restrictions. SELECTION CRITERIA: We aimed to include all RCTs comparing the effects of fibrate monotherapy versus placebo or usual care, or fibrates plus other lipid-modifying drugs versus other lipid-modifying drugs alone. Included studies had a follow-up of at least six months for the primary prevention of CVD events. We excluded trials with clofibrate, because it was withdrawn from the market in 2002. DATA COLLECTION AND ANALYSIS: statistic to measure inconsistency of treatment effects across studies. Using the GRADE approach, we assessed the quality of the evidence and used the GRADE profiler software (GRADEpro GDT) to import data from Review Manager 5 to create 'Summary of findings' tables. MAIN RESULTS: = 74%; very low-quality of evidence). Data on quality of life were not available from any trial. Trials that evaluated fibrates in the background of statins (2 studies) showed no benefits in preventing cardiovascular events. AUTHORS' CONCLUSIONS: Moderate-quality evidence suggests that fibrates lower the risk for cardiovascular and coronary events in primary prevention, but the absolute treatment effects in the primary prevention setting are modest (absolute risk reductions < 1%). There is low-quality evidence that fibrates have no effect on overall or non-CVD mortality. Very low-quality evidence suggests that fibrates are not associated with increased risk for adverse effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Subsequent metaanalyses have also demonstrated similar findings regarding the benefits of fibrates in patients with true dyslipidemia”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [144]
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,638
Heart Disease and Stroke Statistics—2006 Update
Writing Group Members, Thom, T., Haase, N., Rosamond, W. D., Howard, V. J., Rumsfeld, J. S., Manolio, T. A., Zheng, Z., Flegal, K. M., O’Donnell, C. J., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.171600 · Cited by 3,488
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Pedersen, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,098
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Investigating and dealing with publication and other biases in meta-analysis
Sterne, J. A. C., Egger, M., & Smith, G. D. (2001) · BMJ · doi:10.1136/bmj.323.7304.101 · Cited by 2,225
Turner, R. C., Millns, H., Neil, H. A. W., Stratton, I. M., Manley, S. E., Matthews, D. R., & Holman, R. R. (1998) · BMJ · doi:10.1136/bmj.316.7134.823 · Cited by 2,014
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Clofibrate and Niacin in Coronary Heart Disease
Stamler, J. (1975) · JAMA · doi:10.1001/jama.1975.03240160024021 · Cited by 1,750
Graham (2007) · doi:10.1097/01.hjr.0000277983.23934.c9 · Cited by 1,647
Effects of medical therapies on retinopathy progression in type 2 diabetes
The ACCORD Study Group and ACCORD Eye Study Group (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001288 · Cited by 1,311
Published by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
Keech, A., Mitchell, P., Summanen, P., O'Day, J., Davis, T., Moffitt, M., Taskinen, M.-R., Simes, R., Tse, D., Williamson, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61607-9 · Cited by 1,109
Hypertriglyceridemia as a cardiovascular risk factor
Austin, M. A., Hokanson, J. E., & Edwards, K. L. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00031-9 · Cited by 1,066
Oliver, M., Heady, J., Morris, J. N., Cooper, J., Geizerova, H., Gyárfás, I., Green, K., Strasser, T., Macfie, W. G., Scott, E., et al. (1978) · Heart · doi:10.1136/hrt.40.10.1069 · Cited by 1,047
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875
Authors/Task Force Members: Joep Perk (Chairperson) (Sweden)*, G. D. B. (. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312450228 · Cited by 863
Steiner, G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04209-4 · Cited by 849
Hulley, S. B., Rosenman, R. H., Bawol, R. D., & Brand, R. J. (1980) · New England Journal of Medicine · doi:10.1056/nejm198006193022503 · Cited by 702
Keene, D., Price, C., Shun-Shin, M. J., & Francis, D. P. (2014) · BMJ · doi:10.1136/bmj.g4379 · Cited by 513
Briel, M., Ferreira-Gonzalez, I., You, J. J., Karanicolas, P. J., Akl, E. A., Wu, P., Blechacz, B., Bassler, D., Wei, X., Sharman, A., et al. (2009) · BMJ · doi:10.1136/bmj.b92 · Cited by 491
Self-citationEricsson, C.-G., Fairé, U. D., Grip, L., Svane, B., Hamsten, A., & Nilsson, J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91343-4 · Cited by 438
&NA; (1996) · The Endocrinologist · doi:10.1097/00019616-199609000-00019 · Cited by 417
Dietary fat intake and prevention of cardiovascular disease: systematic review
Hooper, L., Summerbell, C., Higgins, J., Thompson, R. L., Capps, N., Smith, G., Riemersma, R., & Ebrahim, S. (2001) · British medical journal · doi:10.1136/bmj.322.7289.757 · Cited by 409
Safety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408
Frick, M. H., Syvänne, M., Nieminen, M. S., Kauma, H., Majahalme, S. K., Virtanen, V., Kesäniemi, Y. A., Pasternack, A. I., & Taskinen, M. (1997) · Circulation · doi:10.1161/01.cir.96.7.2137 · Cited by 389
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
Jones, P. H., & Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.08.076 · Cited by 387
on behalf of the FIELD Study investigators, Davis, T. M. E., Ting, R., Best, J. D., Donoghoe, M. W., Drury, P. L., Sullivan, D. R., Jenkins, A. J., O’Connell, R. L., Whiting, M. J., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-1951-1 · Cited by 371
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate.
Miettinen, M., Turpeinen, O., & Karvonen, M. J. (1979) · Heart · doi:10.1136/hrt.42.3.370 · Cited by 364
Grundy, S. M. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.10.001 · Cited by 353
Mills, E. J., WU, P., Chong, G., Ghement, I., Singh, S., Akl, E. A., Eyawo, O., Guyatt, G., Berwanger, O., & Briel, M. (2011) · QJM · doi:10.1093/qjmed/hcq165 · Cited by 338
Self-citationGrundy, S. M., Arai, H., Barter, P. J., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A. M., Davidson, M. H., Genest, J. J., Kesäniemi, Y. A., et al. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.12.005 · Cited by 334
Rajamani, K., Colman, P. G., Li, L. P., Best, J. D., Voysey, M., D'Emden, M. C., Laakso, M., Baker, J. R., & Keech, A. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60698-x · Cited by 328
Effect of Different Antilipidemic Agents and Diets on Mortality
Studer, M., Briel, M., Leimenstoll, B. M., Glass, T. R., & Bucher, H. C. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.7.725 · Cited by 317
Self-citationGraham, I. D., Atar, D., Borch‐Johnsen, K., Boysen, G., Burell, G. K., Cífková, R., Dallongeville, J., Backer, G. D., Ebrahim, S. B. J., Gjelsvik, B., et al. (2007) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000277984.31558.c4 · Cited by 299
Rabar, S., Harker, M., O'Flynn, N., Wierzbicki, A. S., & On behalf of the Guideline Development Group (2014) · BMJ · doi:10.1136/bmj.g4356 · Cited by 292
Elkeles, R. S., Diamond, J. R., Poulter, C., Dhanjil, S. K., Nicolaides, A. N., Mahmood, S., Richmond, W., Mather, H. M., Sharp, P. S., Feher, M. D., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.641 · Cited by 270
Iestra, J. A., Kromhout, D., van der Schouw, Y. T., Grobbee, D. E., Boshuizen, H. C., & van Staveren, W. A. (2005) · Circulation · doi:10.1161/circulationaha.104.503995 · Cited by 265
Fibrinogen and coronary heart disease--what does it mean?
Assmann, G., Schulte, H., Funke, H., & von Eckardstein, A. (1998) · PubMed · Cited by 256
Ischaemic Heart Disease: A Secondary Prevention Trial Using Clofibrate
Research Committee of the Scottish Society of Physicians (1971) · BMJ · doi:10.1136/bmj.4.5790.775 · Cited by 242
Lee, M., Saver, J. L., Towfighi, A., Chow, J., & Ovbiagele, B. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.020 · Cited by 240
Bezafibrate in men with lower extremity arterial disease: randomised controlled trial
Meade, T., Zuhrie, R., Cook, C., & Cooper, J. (2002) · BMJ · doi:10.1136/bmj.325.7373.1139 · Cited by 208
Secondary causes of hyperlipidemia.
Stone, N. J. (1994) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30179-1 · Cited by 199
Williamson, J. D., Launer, L. J., Bryan, R. N., Coker, L. H., Lazar, R. M., Gerstein, H. C., Murray, A. M., Sullivan, M. D., Horowitz, K. R., Ding, J., et al. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.13656 · Cited by 187
Miller, N., Frieden, T. R., Liu, S. Y., Matte, T., Mostashari, F., Deitcher, D. R., Cummings, K. M., Chang, C. C., Bauer, U. E., & Bassett, M. T. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66615-9 · Cited by 174
Diabetes Intervention Study: Multi-Intervention Trial in Newly Diagnosed NIDDM
Markolf Hanefeld, E., Fischer, S., Schmechel, H., Rothe, G., Schulze, J., Dude, H., Schwanebeck, U., & Julius, U. (1991) · Diabetes Care · doi:10.2337/diacare.14.4.308 · Cited by 166
Fibrates for secondary prevention of cardiovascular disease and stroke
Wang, D., Liu, B., Tao, W., Hao, Z., & Liu, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009580.pub2 · Cited by 142
Steiner, G., Schwartz, L., Shumak, S. L., & Poapst, M. E. (1987) · Circulation · doi:10.1161/01.cir.75.1.124 · Cited by 140
Effect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review
Abourbih, S., Filion, K. B., Joseph, L., Schiffrin, E. L., Rinfret, S., Poirier, P., Pilote, L., Genest, J., & Eisenberg, M. J. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.030 · Cited by 139
Letter: Cross-immunity to influenza B virus strains.
Silva, L. M. D., Mortimer, P. R., & Casemore, D. P. (1974) · BMJ · doi:10.1136/bmj.4.5947.767-c · Cited by 134
GSteiner, LSchwartz, SShumak, & MPoapst (1987) · Circulation · Cited by 119
The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy
Fazio, S., & Linton, M. F. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0104-8 · Cited by 118
Rosenson, R. S., Wolff, D. A., Huskin, A. L., Helenowski, I. B., & Rademaker, A. W. (2007) · Diabetes Care · doi:10.2337/dc07-0015 · Cited by 117
Steiner, G. (1996) · Diabetologia · doi:10.1007/s001250050630 · Cited by 110
Acquired Hyperlipidemia (Secondary Dyslipoproteinemias)
Chait, A., & Brunzell, J. D. (1990) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30324-4 · Cited by 101
Frick, M. H., Heinonen, O. P., Huttunen, J. K., Koskinen, P., Mänttäri, M., & Manninen, V. (1993) · Annals of Medicine · doi:10.3109/07853899309147855 · Cited by 92
A Double-blind Controlled Trial of Clofibrate in the Treatment of Diabetic Retinopathy
Harrold, B. P., Marmion, V. J., & Gough, K. R. (1969) · Diabetes · doi:10.2337/diab.18.5.285 · Cited by 88
Use of Fibrates in the United States and Canada
Jackevicius, C. A. (2011) · JAMA · doi:10.1001/jama.2011.353 · Cited by 82
Controlled trial of clofibrate in cerebral vascular disease.
Acheson, J., & Hutchinson, E. (1972) · Atherosclerosis · doi:10.1016/0021-9150(72)90067-6 · Cited by 78
Chew, G. T., Watts, G. F., Davis, T. M. E., Stuckey, B. G. A., Beilin, L. J., Thompson, P. L., Burke, V., & Currie, P. J. (2008) · Diabetes Care · doi:10.2337/dc08-0118 · Cited by 72
Krysiak, R. G., Gdula‐Dymek, A., Bachowski, R., & Okopień, B. (2010) · Diabetes Care · doi:10.2337/dc10-0272 · Cited by 69
Davidson, M. H., Rosenson, R. S., Maki, K. C., Nicholls, S. J., Ballantyne, C. M., Mazzone, T., Carlson, D. M., Williams, L. A., Kelly, M. T., Camp, H. S., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302926 · Cited by 63
on behalf of the FIELD Study Investigators, d’Emden, M. C., Jenkins, A. J., Li, L., Zannino, D., Mann, K. P., Best, J. D., Stuckey, B. G. A., Park, K., Saltevo, J., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3344-3 · Cited by 49
Bays, H. E., Jones, P. H., Mohiuddin, S. M., Kelly, M. T., Sun, H., Setze, C. M., Buttler, S. M., Sleep, D. J., & Stolzenbach, J. C. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.10.001 · Cited by 49
Pruski, M., Krysiak, R. G., & Okopień, B. (2009) · Diabetes Care · doi:10.2337/dc08-2335 · Cited by 48
Long-term Benefit of High-Density Lipoprotein Cholesterol–Raising Therapy With Bezafibrate
Goldenberg, I., Boyko, V., Tenenbaum, A., Tanné, D., Behar, S., & Guetta, V. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.584 · Cited by 43
Goldenberg, I., Benderly, M., Sidi, R., Boyko, V., Tenenbaum, A., Tanné, D., & Behar, S. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.08.033 · Cited by 43
Ip, C.-K., Jin, D.-M., Gao, J.-J., Meng, Z., Meng, J., Tan, Z., Wang, J.-F., & Geng, D.-F. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.228 · Cited by 43
Fibrates: no ACCORD on their use in the treatment of dyslipidaemia
Wierzbicki, A. S. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833c1e74 · Cited by 39
Derosa, G., Maffioli, P., SALVADEO, S. A. T., Ferrari, I., Gravina, A., Mereu, R., Palumbo, I., D’Angelo, A., & Cicero, A. F. G. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903073159 · Cited by 39
Secondary Prevention With Bezafibrate Therapy for the Treatment of Dyslipidemia
Goldenberg, I., Benderly, M., & Goldbourt, U. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.048 · Cited by 35
Double-blind trial of Atromid-S in exudative diabetic retinopathy.
Cullen, J. F., Town, S. M., & Cj, C. (1974) · PubMed · Cited by 35
Treating lipid abnormalities in patients with type 2 diabetes mellitus.
Steiner, G. (2001) · American Journal of Cardiology · doi:10.1016/s0002-9149(01)02151-8 · Cited by 34
Effects of Fenofibric Acid on Diabetic Macular Edema: The MacuFen study
Massin, P., Pető, T., Ansquer, J.-C., Aubonnet, P., & for the MacuFEN Study Investigators (2014) · Ophthalmic Epidemiology · doi:10.3109/09286586.2014.949783 · Cited by 33
The Treatment of Cerebrovascular Disease With Clofibrate
(1973) · Stroke · doi:10.1161/01.str.4.4.684 · Cited by 30
Yu, Y., Yao, J., Du, J., Bai, R., Sun, L., Sun, G.-H., Song, G., Cao, S.-M., Shi, C., Ba, Y., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0227 · Cited by 28
Aguilar-Salinas, C. A., nel-Salmoacuten, G. F., Meza, E., Montes, J., Gulı́as-Herrero, A., Saacutenchez, L., Monterrubio‐Flores, E., Gonz[aacute]lez-Valdez, H., & Goacutemez-Peacuterez, F. J. (2001) · Metabolism · doi:10.1053/meta.2001.23308 · Cited by 26
Tonkin, A. M., Hunt, D., Voysey, M., Kesäniemi, A., Hamer, A. W., Waites, J. H., Mahar, L., Mann, S., Glasziou, P., Forder, P., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2011.12.004 · Cited by 25
Jamshidi, Y., Flavell, D. M., Hawe, E., MacCallum, P. K., Meade, T. W., & Humphries, S. E. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00002-3 · Cited by 24
Dohmen, K., Tanaka, H., & Haruno, M. (2013) · PubMed · doi:10.15017/1398604 · Cited by 24
Lee, S., Cho, K. I., Kim, J., Ahn, Y. K., Rha, S., Kim, Y.-J., Choi, Y. S., Choi, S. W., Jeon, D. W., Min, P., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.12.042 · Cited by 20
Betteridge, D. J., Durrington, P. N., Fairhurst, G. J., Jackson, G., McEwan, M. S. R., McInnes, G. T., Miller, J. P., Mir, M. A., Reckless, J. P. D., Rees-Jones, D. I., et al. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90232-1 · Cited by 20
Heymans, S. R. B., Luttun, A., Collen, D., & Carmeliet, P. (2000) · Circulation · Cited by 20
Pulmonary Function after Lymphography
White, R., Webb, J. A. W., Tucker, A. K., & Foster, K. (1973) · BMJ · doi:10.1136/bmj.4.5895.775 · Cited by 20
Emmerich, K.-H., Poritis, N., Stelmane, I., Klindzane, M., Erbler, H., Goldsteine, J., & Görtelmeyer, R. (2009) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/s-0028-1109516 · Cited by 19
Numbers needed to treat derived from meta-analysis: a word of caution.
Peterson, D. (2003) · BMJ Evidence-Based Medicine · doi:10.1136/ebm.8.4.104 · Cited by 18
Apolipoproteins and long-term prognosis in coronary heart disease patients
Benderly, M., Boyko, V., & Goldbourt, U. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.08.008 · Cited by 17
Davidson, M. H., Rosenson, R. S., Maki, K. C., Nicholls, S. J., Ballantyne, C. M., Setze, C. M., Carlson, D. M., & Stolzenbach, J. C. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6395-z · Cited by 15
The Use of Fibric Acid Derivatives in Cardiovascular Prevention
Khoury, N., & Goldberg, A. C. (2011) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-011-0128-7 · Cited by 14
Klempfner, R., Goldenberg, I., Fisman, E. Z., Matetzky, S., Amit, U., Shemesh, J., & Tenenbaum, A. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.033 · Cited by 14
Haim, M., Benderly, M., Tanné, D., Matas, Z., Boyko, V., Fisman, E. Z., Tenenbaum, A., Zimlichman, R., Battler, A., Goldbourt, U., et al. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.07.026 · Cited by 13
Farnier, M., Marcereuil, D., Niet, S. D., Ducobu, J., Steinmetz, A., Retterstøl, K., Bryniarski, L., Császár, A., & Vanderbist, F. (2012) · Clinical Drug Investigation · doi:10.2165/11630820-000000000-00000 · Cited by 12
Mulling over the odds of CETP inhibition
von Eckardstein, A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp394 · Cited by 11
Fibrates for primary prevention of cardiovascular disease events
Nordmann, A. J., González, I. F., Kasenda, B., Saccilotto, R. T., Bassler, D., Bhatnagar, N., & Briel, M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009753 · Cited by 9
Self-citation[Evaluation of clofibrate therapy in peripheral arteriopathy].
Tb, B., & Bm, R. (1971) · PubMed · Cited by 8
Chen, Y. P., Chang, K.-C., Tseng, W., Yin, W. H., Chen, J., Lee, Y. T., & Wu, C. C. (2013) · Europe PMC (PubMed Central) · Cited by 7
ATORVASTATIN VS ROSUVASTATIN; FENOFIBRATE AS AN ADD ON: AN EXPLORATORY STUDY
Khan, M. A., Murti, K., Grover, V., Lal, K., Singh, D. P., Das, P. K., & Pandey, K. (2014) · International Journal of Pharmacy and Pharmaceutical Sciences · Cited by 5
Reasner, C. A. (2006) · Current Atherosclerosis Reports · doi:10.1007/s11883-006-0001-4 · Cited by 4
Combined therapy with statins and fibrates for people with dyslipidaemia
Meza, V., Ganduglia, C., & Ciapponi, A. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006969 · Cited by 2
On, T., Шарашкина, Н. В., Novikova, I. M., & Torshkhoeva, K. M. (2010) · PubMed · Cited by 2
Foucher, C., Malicot, K. L., Ansquer, J.-C., Gebski, V., & KEECH, A. C. (2010) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(10)71020-5 · Cited by 1
Combined therapy with statins and fibrates for people with dyslipidaemia
Ciapponi, A., Martí, S. G., Ares, L. R., & Colantonio, L. D. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006969.pub2 · Cited by 1
PCV3 HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND RISK FOR MAJOR CARDIOVASCULAR EVENTS IN MEN AND WOMEN
Webb, S., Simko, R., Laitinen, D. L., & Manthena, S. R. (2009) · Value in Health · doi:10.1016/s1098-3015(10)75368-7 · Cited by 1
Valensi, P. E., Gottlieb, I., Le-Mouhaer, S., & Conte, M. (2010) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(10)70375-5 · Cited by 1
Лямина, Н. П., Карпова, Э. С., Kotelnikova, E. V., & Носенко, А. Н. (2011) · PubMed · Cited by 1
Explaining heterogeneity in meta-analysis: a comparison of methods
Thompson, S. G., & Sharp, S. J. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19991030)18:20
Research works printed but not linked: 8
- Domagala TB Kotula-Horowitz K Januszek R Janczura M Zagajewski J Musial J The effect of fenofibrate therapy on plasma homocysteine levels and endothelial dysfunction in the subjects with metabolic syndrome Journal of Diabetes 2013 46 7
- Kawano, 2013, Effects of combination lipid therapy on lipid profiles in patients with impaired glucose tolerance, Journal of Diabetes, 5, 112
- Arthur, 1971, Trial of clofibrate in the treatment of ischemic heart disease, British Medical Journal, 4, 767
- Scott, 2010, A 6-month randomised study of the combination of fenofibrate and simvastatin in patients with mixed dyslipidaemia at risk of cardiovascular disease not adequately controlled by simvastatin 40 mg alone, European Heart Journal, 31, 390
- Ginsberg, 2010, Effects of combination lipid therapy in type 2 diabetes mellitus, New England Journal of Medicine, 362, 1563, 10.1056/NEJMoa1001282 · DOI · Paper page
- Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org
- Rubins, 1999, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, New England Journal of Medicine, 341, 410, 10.1056/NEJM199908053410604 · DOI · Paper page
- Department of Economic and Social Affairs, 2003, Consolidated list of products whose consumption and/or sale have been banned, withdrawn, severely restricted or not approved by governments. Eighth Issue - Pharmaceuticals
Cited by
Sorted by citations
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 345
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Cheng, H. S., Tan, W., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205055 · Cited by 282
Majeed, Y., Halabi, N. M., Madani, A. Y., Engelke, R., Bhagwat, A. M., Abdesselem, H., Agha, M. V., Vakayil, M., Courjaret, R. J., Goswami, N., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-87759-x · Cited by 220
Metadata
- Authors
- Jakob, T., Nordmann, A. J., Schandelmaier, S., Ferreira-González, I., & Briel, M.
- Affiliations
- University of Basel (CH)
- Vall d'Hebron Hospital; Cardiology Department, Epidemiology Unit; Passeig Vall d'Hebron 119-129 Barcelona Barcelona Spain 08035
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2016-11-16
- Volume
- 2017
- Issue
- 3
- Pages
- CD009753-CD009753
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- PMC
- PMC6464497
- OpenAlex
- W1918267826
- Cited by
- 147
- References
- 129
- Citations by year
- 2026: 2 · 2025: 12 · 2024: 11 · 2023: 25 · 2022: 18 · 2021: 16 · 2020: 16 · 2019: 15 · 2018: 21 · 2017: 8 · 2016: 1
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cochrane Database of Systematic Reviews (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- British Heart Foundation
- European Society of Cardiology
- Medical Research Council
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- fibrates, primary prevention, cardiovascular disease, cardiovascular events, coronary events, triglycerides, lipid-modifying drugs, statins, atherogenic dyslipidemia, mortality, adverse effects, quality of life
- MeSH terms
- Atorvastatin, Hypolipidemic Agents, Bezafibrate, Cardiovascular Diseases, Clofibric Acid, Humans, Middle Aged, Myocardial Infarction, Primary Prevention, Fenofibrate, Gemfibrozil, Simvastatin, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
